AR018185A1 - Compuestos triciclicos substituidos utiles como inhibidores de la liberacion de acidos grasos mediada por spla2 en mamiferos y uso de dichos compuestos enla fabricacion de composiciones para aliviar los efectos patologicos de enfermedades relacionadas con spla2 - Google Patents
Compuestos triciclicos substituidos utiles como inhibidores de la liberacion de acidos grasos mediada por spla2 en mamiferos y uso de dichos compuestos enla fabricacion de composiciones para aliviar los efectos patologicos de enfermedades relacionadas con spla2Info
- Publication number
- AR018185A1 AR018185A1 ARP990101769A ARP990101769A AR018185A1 AR 018185 A1 AR018185 A1 AR 018185A1 AR P990101769 A ARP990101769 A AR P990101769A AR P990101769 A ARP990101769 A AR P990101769A AR 018185 A1 AR018185 A1 AR 018185A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- nitrogen
- spla2
- substituted
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyridine Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Se propone una clase de compuestos tricíclicos y el uso de dichos compuestos para inhibir la liberacion de ácidos grasos mediada por sPLA2 para eltratamiento de afecciones tales como el choque séptico. Los compuestos tricíclicos mencionados corresponden a la formula (I), en la que: A es fenilo opiridilo, donde el nitrogeno está en la posicion 5, 6, 7 u 8; uno de B o D es nitrogeno y el otro es carbono; Z es ciclohexenilo, fenilo, piridilo, donde elnitrogeno está en la posicion 1, 2 o 3, o un anillo heterocíclico de 6 eslabones que tiene un heteroátomo seleccionado entre el grupo compuesto por azufre uoxígeno en la posicion 1, 2 o 3, y nitrogeno en la posicion 1, 2, 3 o 4; la línea de puntos 1 es un enlace sencillo o doble; R20 se seleccionaentre grupos(a), (b) y (c), donde: (a) es -alquilo C5-20, -alquenilo C5-20, -alquinilo C5-20, radicales carbocíclicos o radicales heterocíclicos, o (b) es un miembro de(a) sustituido con uno o más sustituyentes no interferentes, seleccionados independientemente; o (c) es el grupo -(L)-R80; donde (L)- es un grupo de uniondivalente de 1 a 12 átomos, seleccionado entre carbono, hidrogeno, nitrogeno y azufre; donde la combinacion de átomos en -(L)- se selecciona entre el grupocompuesto por (i) solocarbono e hidrogeno, (ii) solo un azufre, (iii) solo un oxígeno, (iv) solo uno o dos nitrogenos e hidrogeno, (v) carbono, hidrogeno ysolo un azufre, y (vi) carbono, hidrogeno y solo oxígeno; y donde R80 es un grupo seleccionado entre (a) o (b); R21es un sustituyente no interferente; R1 es-NHNH2, -NH2 o -CONH2; R2 se selecciona entre el grupo compuesto por -OH y -O(CH2)tR5, donde R5 es H, -CN, -NH2, -CONH2, -CONR9R10, -NHSO2R15; -CONHSO2R15,donde R15 es -alquilo C1-6 o -CF3; fenilo o fenilo sustituido con -CO2H o -CO2-alquilo C1-4; y -(La)-(grupo ácido), donde -(La)- es un conector ácido que tieneuna longitud de conector ácido de 1 a 7, y t es 1-5; R3 se selecciona entre sustituyentes no interferentes, radicales carbocíclicos, radicales carbocíclicossustituidos con sustituyentes no interferentes, radicales heterocíclicos y radicales heterocíclicos sustituidos con sustituyentes no interferentes; o racematos
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6216598A | 1998-04-17 | 1998-04-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR018185A1 true AR018185A1 (es) | 2001-10-31 |
Family
ID=22040624
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990101769A AR018185A1 (es) | 1998-04-17 | 1999-04-16 | Compuestos triciclicos substituidos utiles como inhibidores de la liberacion de acidos grasos mediada por spla2 en mamiferos y uso de dichos compuestos enla fabricacion de composiciones para aliviar los efectos patologicos de enfermedades relacionadas con spla2 |
Country Status (27)
| Country | Link |
|---|---|
| EP (2) | EP0950661B1 (es) |
| JP (1) | JP4435325B2 (es) |
| KR (1) | KR19990083234A (es) |
| CN (1) | CN1235968A (es) |
| AR (1) | AR018185A1 (es) |
| AT (2) | ATE259818T1 (es) |
| AU (1) | AU757454B2 (es) |
| BR (1) | BR9901275A (es) |
| CA (1) | CA2269256A1 (es) |
| CO (1) | CO5080728A1 (es) |
| CZ (1) | CZ137199A3 (es) |
| DE (2) | DE69914951T2 (es) |
| EA (1) | EA003129B1 (es) |
| ES (2) | ES2213668T3 (es) |
| HU (1) | HUP9901219A1 (es) |
| ID (1) | ID23219A (es) |
| IL (1) | IL129484A0 (es) |
| NO (1) | NO991823L (es) |
| NZ (1) | NZ335252A (es) |
| PE (1) | PE20000472A1 (es) |
| PL (1) | PL332564A1 (es) |
| SG (1) | SG106035A1 (es) |
| SV (1) | SV1999000052A (es) |
| TR (1) | TR199900842A2 (es) |
| TW (1) | TW555760B (es) |
| YU (1) | YU19099A (es) |
| ZA (1) | ZA992773B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999009978A1 (en) * | 1997-08-28 | 1999-03-04 | Eli Lilly And Company | Method for treatment of non-rheumatoid athritis |
| WO2001074817A1 (fr) * | 2000-03-30 | 2001-10-11 | Yamanouchi Pharmaceutical Co., Ltd. | Derives d'hydrazide |
| EP1303262A2 (en) * | 2000-07-14 | 2003-04-23 | Eli Lilly And Company | Use of a spla2 inhibitor for the treatment of sepsis |
| DE60120758T2 (de) * | 2000-12-18 | 2007-05-16 | Eli Lilly And Co., Indianapolis | Tetracyclische derivate als spla2 inhibitoren |
| EP1395554B1 (en) | 2001-03-28 | 2007-02-14 | Eli Lilly And Company | Substituted carbazoles as inhibitors of spla2 |
| ES2252497T3 (es) * | 2001-08-09 | 2006-05-16 | Eli Lilly And Company | Derivados ciclohept(b)indol como inhibidores de spla2. |
| EP1423366A1 (en) | 2001-08-09 | 2004-06-02 | Eli Lilly And Company | Cyclopenta b ! indole derivatives as spla2 inhibitors |
| US6992100B2 (en) | 2001-12-06 | 2006-01-31 | Eli Lilly And Company | sPLA2 inhibitors |
| CA2585967A1 (en) | 2004-11-01 | 2006-05-11 | Wyeth | Substituted indolizines and derivatives as cns agents |
| EP2476680B1 (en) | 2008-01-11 | 2014-08-27 | Albany Molecular Research, Inc. | (1-Azinone)-Substituted Pyridoindoles |
| WO2011003021A1 (en) | 2009-07-01 | 2011-01-06 | Albany Molecular Research, Inc. | Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof |
| US8993765B2 (en) | 2010-12-21 | 2015-03-31 | Albany Molecular Research, Inc. | Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof |
| LT2697223T (lt) * | 2011-04-14 | 2016-10-10 | Actelion Pharmaceuticals Ltd. | 7-(heteroaril-amino)-6,7,8,9-tetrahidropirido[1,2-a]indolacto rūgšties dariniai ir jų, kaip prostaglandino d2 receptoriaus moduliatorių, panaudojimas |
| LT2825542T (lt) | 2012-03-16 | 2016-12-27 | Vitae Pharmaceuticals, Inc. | Kepenų x receptoriaus moduliatoriai |
| RS55166B1 (sr) | 2012-03-16 | 2017-01-31 | Vitae Pharmaceuticals Inc | Modulatori x receptora iz jetre |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3979391A (en) * | 1972-11-22 | 1976-09-07 | Sterling Drug Inc. | 1,2,3,4-Tetrahydrocarbazoles |
| PT95692A (pt) * | 1989-10-27 | 1991-09-13 | American Home Prod | Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase |
| IL109311A0 (en) * | 1993-04-16 | 1994-07-31 | Lilly Co Eli | 1H-indole-3-acetamide sPla2 inhibitors |
| IL109309A (en) * | 1993-04-16 | 2000-06-29 | Lilly Co Eli | 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them |
| WO1996003383A1 (en) * | 1994-07-21 | 1996-02-08 | Eli Lilly And Company | INDOLIZINE sPLA2 INHIBITORS |
| AU1289797A (en) * | 1995-12-13 | 1997-07-03 | Eli Lilly And Company | Naphthyl acetamides as spla2 inhibitors |
| CZ136899A3 (cs) * | 1996-10-30 | 1999-09-15 | Eli Lilly And Company | Substituované tricyklické sloučeniny |
| CA2304482A1 (en) * | 1997-09-26 | 1999-04-08 | Eli Lilly And Company | Method for the treatment of cystic fibrosis |
| CA2310250A1 (en) * | 1997-11-14 | 1999-05-27 | August Masaru Watanabe | Treatment for alzheimer's disease |
-
1999
- 1999-04-15 IL IL12948499A patent/IL129484A0/xx unknown
- 1999-04-15 ID IDP990342D patent/ID23219A/id unknown
- 1999-04-16 CN CN99108097A patent/CN1235968A/zh active Pending
- 1999-04-16 NZ NZ335252A patent/NZ335252A/xx unknown
- 1999-04-16 EA EA199900304A patent/EA003129B1/ru not_active IP Right Cessation
- 1999-04-16 CZ CZ991371A patent/CZ137199A3/cs unknown
- 1999-04-16 AT AT01203116T patent/ATE259818T1/de not_active IP Right Cessation
- 1999-04-16 CO CO99022891A patent/CO5080728A1/es unknown
- 1999-04-16 SV SV1999000052A patent/SV1999000052A/es not_active Application Discontinuation
- 1999-04-16 ES ES01203116T patent/ES2213668T3/es not_active Expired - Lifetime
- 1999-04-16 YU YU19099A patent/YU19099A/sh unknown
- 1999-04-16 TR TR1999/00842A patent/TR199900842A2/xx unknown
- 1999-04-16 PL PL99332564A patent/PL332564A1/xx not_active Application Discontinuation
- 1999-04-16 DE DE69914951T patent/DE69914951T2/de not_active Expired - Fee Related
- 1999-04-16 AR ARP990101769A patent/AR018185A1/es not_active Application Discontinuation
- 1999-04-16 EP EP99302969A patent/EP0950661B1/en not_active Expired - Lifetime
- 1999-04-16 SG SG9901844A patent/SG106035A1/en unknown
- 1999-04-16 ES ES99302969T patent/ES2210979T3/es not_active Expired - Lifetime
- 1999-04-16 ZA ZA9902773A patent/ZA992773B/xx unknown
- 1999-04-16 DE DE69912670T patent/DE69912670T2/de not_active Expired - Fee Related
- 1999-04-16 TW TW088106131A patent/TW555760B/zh not_active IP Right Cessation
- 1999-04-16 HU HU9901219A patent/HUP9901219A1/hu unknown
- 1999-04-16 AU AU23818/99A patent/AU757454B2/en not_active Ceased
- 1999-04-16 BR BR9901275-8A patent/BR9901275A/pt not_active IP Right Cessation
- 1999-04-16 CA CA002269256A patent/CA2269256A1/en not_active Abandoned
- 1999-04-16 PE PE1999000321A patent/PE20000472A1/es not_active Application Discontinuation
- 1999-04-16 KR KR1019990013439A patent/KR19990083234A/ko not_active Application Discontinuation
- 1999-04-16 NO NO991823A patent/NO991823L/no not_active Application Discontinuation
- 1999-04-16 AT AT99302969T patent/ATE254128T1/de not_active IP Right Cessation
- 1999-04-16 EP EP01203116A patent/EP1156050B1/en not_active Expired - Lifetime
- 1999-04-16 JP JP10965699A patent/JP4435325B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR018593A1 (es) | COMPUESTOS TRICICLICOS SUSTITUIDOS, FORMULACIoN FARMACÉUTICA QUE LO COMPRENDE, USO DE DICHO COMPUESTO PARA FABRICAR UN MEDICAMENTO uTIL PARA INHIBIR SELECTIVAMENTE SPLA2 Y ALIVIAR EFECTOS PATOLoGICOS DE ENFERMEDADES RELACIONADAS | |
| AR018185A1 (es) | Compuestos triciclicos substituidos utiles como inhibidores de la liberacion de acidos grasos mediada por spla2 en mamiferos y uso de dichos compuestos enla fabricacion de composiciones para aliviar los efectos patologicos de enfermedades relacionadas con spla2 | |
| CO4920250A1 (es) | Compuestos heterociclicos utiles en la inhibicion de la spla2 | |
| ES2055762T3 (es) | Composicion de un producto lubricante. | |
| ECSP056222A (es) | Derivados de indazolil(indolil)maleimida sustituidoscomo inhibidores de cinasa | |
| EA200600358A1 (ru) | Фенил- или пиридиламидные соединения в качестве антагонистов простагландина е2 | |
| ME00768B (me) | Derivati supstituisanih benzol sulfonamida kao pro-lekovi cox-2 inhibitora | |
| DOP2002000482A (es) | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares | |
| BR0314586A (pt) | Composições de tratamento para furos de sondagem com fase de óleo de baixa toxicidade | |
| CO4970702A1 (es) | Quinolonas antimicrobianas, sus composiciones y sus usos | |
| UY24908A1 (es) | Derivados del ácido hexanoico | |
| BR9915895A (pt) | Composto, uso do mesmo, processo para prepará-lo, método para o tratamento de um mamìfero, incluindo o homem, de condições resultantes de nìveis de circulação elevados de apob-100, e, composição farmacêutica | |
| FR2361889A1 (fr) | Nouveaux derives de 1-(benzazolyalcoyl)piperidine | |
| GB930136A (en) | Improvements in or relating to lubricating compositions | |
| ES2159347T3 (es) | Naftil-acetamidas como inhibidores de spla2. | |
| CO5040004A1 (es) | 2-4-diamino-1,3,5-triazinas, su preparacion y empleo como herbicidas y fitorreguladores | |
| BG60338B2 (en) | Thienothiazines | |
| ES2195182T3 (es) | Fenil glioxamidas como inhibidores de spla2. | |
| GB9007338D0 (en) | Chemical compounds | |
| ES2174034T3 (es) | Naftilglioxamidas como inhibidores de spla2 | |
| GB1257978A (es) | ||
| AR018652A1 (es) | Inhibidor de catepsina k del tipo pirrolidinona, composicion farmaceuticamente eficaz, usos de dichos compuestos para preparar medicamentos, yprocedimiento para producir dichos inhibidores | |
| PE20001052A1 (es) | Inhibidores de hiv proteasa | |
| ES2171306T3 (es) | Compuesto bajo la forma de isomero geometrico puro o de una mezcla de estos isomeros. | |
| PT90840A (pt) | Processo para a preparcao de 3-aminosidnoniminas substituidas e de composicoes farmaceuticas que as contem |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |